stocktitan.net / .stocktitan-net / Page 7

Ultragenyx Pharmaceutical strengthens team with strategic RSU grants to 15 new non-executive officers, featuring four-year vesting schedule to drive long-term retention.

AtlasClear (ATCH) implements strategic 1-for-60 reverse split to strengthen share structure. Learn how this corporate action impacts stockholders and trading.

FDA issues Complete Response Letter for Lexicon's diabetes drug Zynquista. Company pivots to promising LX9211 development for neuropathic pain, with key data expected Q1 2025.

Major institutional investor BlackRock acquires significant 3% stake in sleep therapy innovator Nyxoah, signaling growing interest in medical device sector.

Mining firm secures important funding through private placement, issuing 18.2M shares to advance Canadian exploration initiatives with tax benefits for subscribers.

Intelligent Living Application Group sees massive revenue growth to $4.47M and dramatic profit improvement, while continuing strategic investments in smart lock R&D.

Xcel Brands reports improved non-GAAP metrics and secures $10M financing despite revenue challenges. Key highlights include 50% cost reduction and enhanced liquidity position.

Michigan's leading financial institution, with $5.3B in assets, prepares to release Q4 2024 performance data. Join top executives for detailed insights into the bank's latest results.

Camden National clears final regulatory hurdles for Northway Financial acquisition, marking significant New England market expansion. Key merger completion set for early 2025.

Mosaic declares quarterly dividend of $0.22 per share, payable March 20, 2025. Learn about the fertilizer giant's latest shareholder distribution and payment details.